Therefore, amplification of MYCN can also involve ALK amplification, and neuroblastoma patients bearing both MYCN amplification and ALK mutations are characterized by an unfavorable aggressive neuroblastoma phenotype [26]. The gene discussed is ALK; the disease is neuroblastoma.